OrbiMed’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

OrbiMed’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28,322	Closed	-$418K	–	156
2022 Q1	$418K	Hold	28,322	–	–	0.01%	142
2021 Q4	$1.36M	Hold	28,322	–	–	0.02%	154
2021 Q3	$4.13M	Sell	28,322 -39,778	-58%	-$5.16M	0.05%	156
2021 Q2	$7.87M	Hold	68,100	–	–	0.08%	138
2021 Q1	$6.56M	Buy	+68,100	New	+$8.89M	0.06%	135

Other funds holding LABP

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OrbiMed's LABP Position: Q2 2022 in Review

OrbiMed sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2022, closing a stake of 28,322 shares — an estimated $418K sold.

OrbiMed first reported a position in LABP in Q1 2021 and held it in 5 quarters. The position peaked at $7.87M in Q2 2021. 34 funds tracked by Wall St. Rank hold LABP as of Q2 2022.

OrbiMed reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
OrbiMed sold 28,322 Landos Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $418K.
OrbiMed first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
OrbiMed's Landos Biopharma, Inc. Common Stock position peaked at $7.87M in Q2 2021.
34 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2022.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.